A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Taiho Oncology, Inc.
AstraZeneca
Seagen Inc.
Incyte Corporation
Incyte Corporation
Crossbow Therapeutics, Inc.
Takeda
Blueprint Medicines Corporation
Taiho Oncology, Inc.
Blueprint Medicines Corporation
Disc Medicine, Inc
Novartis
BeOne Medicines
Disc Medicine, Inc
Chengdu Zenitar Biomedical Technology Co., Ltd
Ossium Health, Inc.
Orca Biosystems, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
Blueprint Medicines Corporation
Chordia Therapeutics, Inc.
Italfarmaco
Cullinan Therapeutics Inc.
GluBio Therapeutics Inc.
MacroGenics
Terns, Inc.
Enliven Therapeutics
iOMEDICO AG
medac GmbH
Celgene
Ascentage Pharma Group Inc.
Bristol-Myers Squibb
Rigel Pharmaceuticals
Ellipses Pharma
BlossomHill Therapeutics
Ryvu Therapeutics SA
Novartis
Novartis
Ossium Health, Inc.
Hangzhou GluBio Pharmaceutical Co., Ltd.
Curis, Inc.
PharmaEssentia
Enliven Therapeutics
Servier
Ascentage Pharma Group Inc.
Cogent Biosciences, Inc.
Mabwell (Shanghai) Bioscience Co., Ltd.
Tr1X, Inc.
Jemincare
Hikma Pharmaceuticals LLC